Company intelligence / Profile preview

mcePharma

(HQ) Stachovice / Bilovec region, Czech Republicmcepharma.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

mcePharma has developed and commercialized patented orally disintegrating tablet formulations for food supplements, including a US-patented curcumin ODT product. The company’s products are supported by scientific studies demonstrating improved solubility and absorption of active ingredients. They offer contract manufacturing, private label solutions, and have expanded their GMP-certified production capabilities following acquisition by Brenntag in June 2025.

Therapeutic areas: OtherImmunology
Modalities: Small molecule (for dietary supplements such as curcumin, astaxanthin, etc.)Protein (e.g., lactoferrin-based products)
Industry: Food & Nutrition

Partnerships

Brenntag Specialtiesvarious B2B/B2C distribution partners globally

Beyond the preview

Go deeper on mcePharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mcePharma.

Explore the full profile